- Home
- Publications
- Publication Search
- Publication Details
Title
New antibiotics for Gram-negative pneumonia
Authors
Keywords
-
Journal
European Respiratory Review
Volume 31, Issue 166, Pages 220119
Publisher
European Respiratory Society (ERS)
Online
2022-12-21
DOI
10.1183/16000617.0119-2022
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- New Antibiotics for Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia
- (2022) Matteo Bassetti et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
- (2022) Courtney J. Scott et al. ANNALS OF PHARMACOTHERAPY
- Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii
- (2022) Marco Falcone et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane-tazobactam in nosocomial pneumonia
- (2022) Francisco Javier Candel et al. Revista Espanola de Quimioterapia
- Ceftolozane/tazobactam versus colistin in the treatment of ventilator-associated pneumonia due to extensively drug-resistant Pseudomonas aeruginosa
- (2022) Bence Mogyoródi et al. Scientific Reports
- Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns
- (2022) Muluneh Assefa Pneumonia
- An overview of cilastatin + imipenem + relebactam as a therapeutic option for hospital-acquired and ventilator-associated bacterial pneumonia: evidence to date
- (2021) Júlia Sellarès-Nadal et al. EXPERT OPINION ON PHARMACOTHERAPY
- Ceftolozane/tazobactam and imipenem/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards – SMART United States 2017-2019
- (2021) Sibylle H Lob et al. Open Forum Infectious Diseases
- Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
- (2021) Sara Alosaimy et al. Open Forum Infectious Diseases
- Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections
- (2021) Laura Puzniak et al. Infectious Diseases and Therapy
- Ceftazidime/avibactam resistance is associated with different mechanisms in KPC-producing Klebsiella pneumoniae strains
- (2021) Sara Cavallini et al. ACTA MICROBIOLOGICA ET IMMUNOLOGICA HUNGARICA
- Ceftobiprole: a clinical view
- (2021) Pedro María Martínez Pérez-Crespo et al. Revista Espanola de Quimioterapia
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- (2020) Antonio Vena et al. CLINICAL INFECTIOUS DISEASES
- Activity of Plazomicin Tested against Enterobacterales Isolates Collected from U.S. Hospitals in 2016–2017: Effect of Different Breakpoint Criteria on Susceptibility Rates among Aminoglycosides
- (2020) Mariana Castanheira et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy
- (2020) Eszter Tichy et al. CLINICAL THERAPEUTICS
- Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
- (2020) Andrea Novelli et al. Expert Review of Anti-Infective Therapy
- Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study)
- (2020) Matteo Bassetti et al. Open Forum Infectious Diseases
- A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
- (2020) Ivan Titov et al. CLINICAL INFECTIOUS DISEASES
- Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia
- (2020) Francesco Amati et al. SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
- Treatment of extended-spectrum β-lactamases infections
- (2020) Matteo Bassetti et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Treatment of Bloodstream Infections Due to Gram-Negative Bacteria with Difficult-to-Treat Resistance
- (2020) Matteo Bassetti et al. Antibiotics-Basel
- Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens
- (2019) Ilias Karaiskos et al. Expert Opinion on Drug Metabolism & Toxicology
- Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms
- (2019) Pranita D Tamma et al. Journal of the Pediatric Infectious Diseases Society
- Plazomicin for Infections Caused by Carbapenem-Resistant Enterobacteriaceae
- (2019) James A. McKinnell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Community-acquired Pneumonia and Hospital-acquired Pneumonia
- (2019) Charles W. Lanks et al. MEDICAL CLINICS OF NORTH AMERICA
- Intrapulmonary pharmacokinetics of cefiderocol, a novel siderophore cephalosporin, in healthy adult subjects
- (2019) Takayuki Katsube et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology
- (2019) Ester del Barrio-Tofiño et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftolozane/Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance
- (2019) Vidmantas Petraitis et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro Activity of Imipenem-Relebactam Alone or in Combination with Amikacin or Colistin against Pseudomonas aeruginosa
- (2019) Tomefa E. Asempa et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas Aeruginosa
- (2019) Jason M Pogue et al. CLINICAL INFECTIOUS DISEASES
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Ceftobiprole: drug evaluation and place in therapy
- (2019) Daniele Roberto Giacobbe et al. Expert Review of Anti-Infective Therapy
- Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
- (2019) Marin H Kollef et al. LANCET INFECTIOUS DISEASES
- Prevalence and risk factors for Enterobacteriaceae in patients hospitalized with community‐acquired pneumonia
- (2019) David Villafuerte et al. RESPIROLOGY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Aztreonam Combination Therapy: An Answer to Metallo-β-Lactamase–Producing Gram-Negative Bacteria?
- (2019) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- The role of new β-lactamase inhibitors in gram-negative infections
- (2019) Antonio Vena et al. CURRENT OPINION IN INFECTIOUS DISEASES
- Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam
- (2018) Melissa D. Barnes et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections
- (2018) Ryan K. Shields et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Intrapulmonary Pharmacokinetics of Relebactam, a Novel β-Lactamase Inhibitor, Dosed in Combination with Imipenem-Cilastatin in Healthy Subjects
- (2018) Matthew L. Rizk et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
- (2018) Toshiaki Aoki et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii
- (2018) Harald Seifert et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- OUP accepted manuscript
- (2018) JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
- (2018) Antoni Torres et al. LANCET INFECTIOUS DISEASES
- A Therapeutic Strategy for All Pneumonia Patients: A 3-Year Prospective Multicenter- Cohort Study Using Risk Factors for Multidrug Resistant Pathogens To Select Initial Empiric Therapy
- (2018) Takaya Maruyama et al. CLINICAL INFECTIOUS DISEASES
- Population Pharmacokinetic Modelling of Ceftazidime and Avibactam in the Plasma and Epithelial Lining Fluid of Healthy Volunteers
- (2018) Richard Dimelow et al. Drugs in research & development
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antimicrobial activity of ceftolozane–tazobactam tested against gram-negative contemporary (2015–2017) isolates from hospitalized patients with pneumonia in US medical centers
- (2018) Cecilia G. Carvalhaes et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- CLINICAL CHARACTERISTICS AND PROGNOSIS OF INFECTIONS CAUSED BY OXA-48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE IN PATIENTS TREATED WITH CEFTAZIDIME-AVIBACTAM
- (2018) C. De la Calle et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
- (2018) George H Talbot et al. JOURNAL OF INFECTIOUS DISEASES
- Intrinsic, adaptive and acquired antimicrobial resistance in Gram-negative bacteria
- (2017) Mohsen Arzanlou et al. Essays in Biochemistry
- International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia
- (2017) Antoni Torres et al. EUROPEAN RESPIRATORY JOURNAL
- Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity againstPseudomonas aeruginosa
- (2016) Akinobu Ito et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Global Dissemination ofblaKPCinto Bacterial Species beyond Klebsiella pneumoniae andIn VitroSusceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam
- (2016) Krystyna M. Kazmierczak et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroSusceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
- (2016) Wright W. Nichols et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms: a case series from the compassionate-use program
- (2016) Elizabeth Temkin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Activity of Ceftazidime-Avibactam against Extended-Spectrum- and AmpC β-Lactamase-Producing Enterobacteriaceae Collected in the INFORM Global Surveillance Study from 2012 to 2014
- (2016) James A. Karlowsky et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Community-Acquired Pneumonia Due to Multidrug- and Non–Multidrug-Resistant Pseudomonas aeruginosa
- (2016) Catia Cillóniz et al. CHEST
- Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.
- (2016) Ryan K. Shields et al. CLINICAL INFECTIOUS DISEASES
- Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations
- (2016) Antonio Torres et al. CLINICAL PHARMACOKINETICS
- Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
- (2016) George G. Zhanel et al. DRUGS
- Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study
- (2016) D. Koulenti et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects
- (2015) Eric Wenzler et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study
- (2015) Marta Tato et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases
- (2015) Scott J. Hecker et al. JOURNAL OF MEDICINAL CHEMISTRY
- Phase I, Open-Label, Safety and Pharmacokinetic Study To Assess Bronchopulmonary Disposition of Intravenous Eravacycline in Healthy Men and Women
- (2014) Kevin P. Connors et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A 16-Year Prospective Study of Community-Onset Bacteremic Acinetobacter Pneumonia
- (2014) Joshua S. Davis et al. CHEST
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
- (2014) S. S. Awad et al. CLINICAL INFECTIOUS DISEASES
- Complications of Mechanical Ventilation — The CDC's New Surveillance Paradigm
- (2013) Michael Klompas NEW ENGLAND JOURNAL OF MEDICINE
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
- (2012) Susan C. Nicholson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Intrapulmonary penetration of ceftolozane/tazobactam and piperacillin/tazobactam in healthy adult subjects
- (2012) G. Chandorkar et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Spectrum of practice in the diagnosis of nosocomial pneumonia in patients requiring mechanical ventilation in European intensive care units
- (2010) Despoina Koulenti et al. CRITICAL CARE MEDICINE
- Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates
- (2010) D. M. Livermore et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: diagnosis, incidence and predictors
- (2009) H. von Baum et al. EUROPEAN RESPIRATORY JOURNAL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More